AI MARKET SCANNING

InflaRx NV

📅 Next Catalyst: Nov 09, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +2.52%
MAX GAP RECORD +43.90%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $IFRX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+0.00%
May 06, 2026 Earnings Release 2026-05-06 (BEFORE OPEN)
+29.44%
Mar 19, 2026 Earnings Release 2026-03-19 (BEFORE OPEN)
-1.14%
Nov 10, 2025 Earnings Release 2025-11-10 (BEFORE OPEN)
+43.90%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-4.76%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+0.00%
Mar 20, 2025 Earnings Release 2025-03-20 (BEFORE OPEN)
-5.47%

VOLATILITY & GAP BIAS

AVG GAP MOVE 10.5%
Bullish Gaps (5)
Bearish Gaps (6)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $IFRX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗